Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 10/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HSD11B2 | P80365 | 5/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | SCN1A | P35498 | 1/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.34 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15831171 | 0.83 | GLA (0.47) | HSD11B1GLAALDH1A1TSHRSCN9A | |
| SCHEMBL233311 | 0.82 | HSD11B1 (0.44) | HSD11B1HSD11B2 | |
| SCHEMBL1035514 | 0.78 | GLA (0.43) | HSD11B1GLAALDH1A1TSHRHSD11B2 | |
| SCHEMBL13495293 | 0.78 | GLA (0.43) | HSD11B1GLAALDH1A1TSHRHSD11B2 | |
| SCHEMBL905300 | 0.77 | GLA (0.57) | GLAALDH1A1TSHRMEN1KMT2A | |
| SCHEMBL1844624 | 0.77 | GLA (0.42) | HSD11B1GLAALDH1A1TSHRHSD11B2 | |
| SCHEMBL1844621 | 0.77 | GLA (0.42) | HSD11B1GLAALDH1A1TSHRHSD11B2 | |
| SCHEMBL328838 | 0.77 | GLA (0.42) | HSD11B1GLAALDH1A1TSHRHSD11B2 | |
| SCHEMBL1844620 | 0.77 | GLA (0.42) | HSD11B1GLAALDH1A1TSHRHSD11B2 | |
| SCHEMBL1896218 | 0.77 | GLA (0.42) | HSD11B1GLAALDH1A1TSHRHSD11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245534-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | ABBOTT LABORATORIES | 2005-11-03 | — | — | US | disclosed |
| US-6891004-B2 | Transition metal catalyst component for polymerization, and method for producing a polymer by means thereof | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2005-05-10 | — | — | US | disclosed |
| US-20030149201-A1 | Transition metal catalyst component for polymerization, and method for producing a polymer by means thereof | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 2003-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245534-A1 | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885GLA 1268/4885ALDH1A1 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.